Evaluation of the 'Quadrella' at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy
| Autor: | S. Serey-eiffel, Pierre Callerot, Benoit Rousseau, Ulrike Schick, J.-P. Malhaire, Jean-Baptiste Coquet, G. Goasduff, Antoine Valeri, Nicolas Boussion, Alexandre Fourcade, Georges Fournier, Olivier Pradier, F. Delage |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Prostate adenocarcinoma
Biochemical recurrence Male medicine.medical_specialty Time Factors Urinary system medicine.medical_treatment Brachytherapy 030232 urology & nephrology Urology Adenocarcinoma 03 medical and health sciences Prostate cancer 0302 clinical medicine Quality of life Erectile Dysfunction Prostate Surveys and Questionnaires medicine Humans Radiology Nuclear Medicine and imaging Aged business.industry Penile Erection Rectum Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Erectile dysfunction medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Neoplasm Grading business Prostate brachytherapy Follow-Up Studies |
| Zdroj: | Brachytherapy. 17(5) |
| ISSN: | 1873-1449 |
| Popis: | Purpose “Quadrella” index has been recently developed to assess oncological and functional outcomes after prostate brachytherapy (PB). We aimed to evaluate this index at 1, 2, and 3 years, using validated questionnaires, assessed prospectively. Methods and Materials From 08/2007 to 01/2013, 193 patients underwent 125Iodine PB for low-risk or favorable intermediate-risk prostate adenocarcinoma. Inclusion criteria were as follows: no incontinence (International Continence Society Index initial score = 0) and good erectile function (International Index of Erectile Function–5 items: >16). One hundred patients were included (mean age: 64 y). Postimplantation intake of phosphodiesterase inhibitors was not considered as failure. The “Quadrella” index was defined by the absence of biochemical recurrence (Phoenix criteria), significant erectile dysfunction (ED) (Index of Erectile Function–5 items: >16), urinary toxicity (UT) (International Prostate Score Symptom [IPSS] 15 with ΔIPSS Results At 12 months, 90 patients were evaluable: 42/90 (46.7%) achieved Quadrella. The main criteria for failure were as follows: ED in 77.1% (37/48) of cases, RT in 20.8% (10/48) of cases, and UT in 12.5% (9/57) of cases. At 24 and 36 months, 59.3% (48/81) and 61.1% (44/72) of patients achieved Quadrella, respectively. The main cause of failure was ED in 69.7% (23/33) and 85.7% (24/28) of cases, while RT was involved in 21.2% (7/33) and in 3.6% (1/28) of cases, and UT in 9.1% (3/33) and 3.6% (1/28) of cases. Only one case of biochemical recurrence was observed (i.e., 1/28 = 3.6% at 3 y). Conclusions The Quadrella can be used at 1, 2, and 3 years after PB. It allows to take into account the urinary and RT specific to PB. ED was the main cause of failure. This index will be useful to assess midterm and long-term results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|